# Cook Enforcer Post-Market Study

Study · id `cardio:ct-nct03552289` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03552289](<https://clinicaltrials.gov/study/NCT03552289>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03552289

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.

## Technical summary

Registry record NCT03552289. Randomized; no masking; primary purpose treatment. Start 2018-08-07 (actual); primary completion 2019-05-29 (actual). Results posted on 2020-08-24.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 211 participants (enrolled count; ClinicalTrials.gov record NCT03552289, source copy `cardio:ctgov-nct03552289-2020-10-19`, retrieved 2026-10-26)
- Started: 2018-08-07 (actual) (ClinicalTrials.gov record NCT03552289, source copy `cardio:ctgov-nct03552289-2020-10-19`, retrieved 2026-10-26)
- Primary completion: 2019-05-29 (actual) (ClinicalTrials.gov record NCT03552289, source copy `cardio:ctgov-nct03552289-2020-10-19`, retrieved 2026-10-26)
- Completion: 2019-08-27 (actual) (ClinicalTrials.gov record NCT03552289, source copy `cardio:ctgov-nct03552289-2020-10-19`, retrieved 2026-10-26)
- Results first posted: 2020-08-24 (ClinicalTrials.gov record NCT03552289, source copy `cardio:ctgov-nct03552289-2020-10-19`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03552289, source copy `cardio:ctgov-nct03552289-2020-10-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03552289-2020-10-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cook Enforcer Post-Market Study
- Condition: End-Stage Renal Disease
- Intervention (Device): Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
- Intervention (Device): Conventional angioplasty balloon catheters
- Lead sponsor: Cook Research Incorporated
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Cook Research Incorporated (`cardio:org-cook-research-incorporated`)

## Provenance

Content hash: f1278b3f212ec020bef257bf2fe745b358b74afde1eba1b00bff65f8d33c25d1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
